India's pharmaceutical oversight: A lopsided solution to manufacturing quality issues
India's pharmaceutical sector faces scrutiny over manufacturing quality, with a recent government move to make it mandatory for all drug manufacturers to adopt the revised Schedule M of the Drugs and Cosmetics Rules. While this is a step towards improving quality, the article argues it's a lopsided solution. The focus on manufacturing standards without addressing the broader ecosystem, including regulatory oversight, testing, and market incentives, is insufficient. Many small and medium-sized enterprises (SMEs) struggle with compliance costs, and the current system often prioritizes cost-cutting over quality, especially for generics. A comprehensive approach is needed to ensure genuine quality improvement.
Key Points
- India's pharmaceutical industry faces criticism for quality issues, particularly concerning generic drugs.
- The government mandated revised Schedule M of the Drugs and Cosmetics Rules for all manufacturers to improve quality.
- The article argues this solution is lopsided, as it focuses solely on manufacturing standards without addressing broader systemic issues.
- Challenges include inadequate regulatory oversight, insufficient testing infrastructure, and market pressures on SMEs.
- A holistic approach is required, encompassing regulatory strengthening, market incentives for quality, and support for SMEs to upgrade.
Exam Facts
- Revised Schedule M of the Drugs and Cosmetics Rules.
- Deadline for compliance for large manufacturers: August 1, 2026.
- Deadline for compliance for small/medium manufacturers: February 1, 2027.
- India is the world's third-largest producer of pharmaceuticals by volume.
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.